The Hybrid Approach in CAD with Restore® DEB: Use and Clinical Outcomes in the HYPER Study

Published: 18 June 2024

  • Views:

    Views Icon 1320

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). 

This video series is supported by

Learning Objectives

  • Gain insights into the findings of the HYPER Study presented by Dr Ielasi, focusing on the hybrid approach combining a drug-eluting stent and the Restore® drug-coated balloon (DEB)
  • Understand the technological features and benefits of the Restore® DEB as explained by Dr Ielasi during the video interview
  • Comprehend the study design, including participant selection criteria and clinical outcomes of the HYPER Study
  • Recognise the significance of procedural success rates DoCE rates in evaluating the effectiveness and safety of the hybrid approach
  • Appreciate the long-term stability of favourable outcomes, including low DoCE rates, observed up to the 3-year follow-up period in the HYPER Study
  • Interpret the implications of the HYPER Study findings for clinical practice, particularly in the context of coronary artery disease management and treatment strategies involving drug-eluting stents and drug-coated balloons

Target Audience

  • Interventional Cardiologists

More from this programme

Part 1

The HYPER Study Findings

1 session
The HYPER Study Findings: Hybrid Approach with Restore® DEB Shows Promising Long-Term Results Watch now

Part 2

HYPER EXTEND

1 session
HYPER EXTEND: 2-Year Follow-up Following a Hybrid Strategy Using DES and DCB in Diffuse CAD Watch now

Part 3

DEB & DES in the Treatment of Diffuse CAD

1 session
EuroPCR 22: DEB & DES in the Treatment of Diffuse CAD Watch now

About the episode

In this short summary interview, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) shares the findings from the pilot observational study, HYPER. Presented first at EuroPCR 22, this trial investigated the safety and efficacy of the hybrid approach DES/DCB in treating de-novo diffuse lesions.

Faculty Biographies

Alfonso Ielasi

Alfonso Ielasi

Interventional Cardiologist

Dr Alfonso Ielasi is an Interventional Cardiologist at IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, IT.

Dr Ielasi's interests include interventional cardiovascular therapies of acute coronary syndromes, unprotected left main disease, complex coronary artery disease and aortic valve stenosis.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.